指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症肺结核诊断和治疗专家共识

[Expert consensus on the diagnosis and treatment of severe pulmonary tuberculosis].
指南 / 共识 · Zhonghua Jie He He Hu Xi Za Zhi · 2025-01-01
一句话结论中华医学会结核病学分会组织专家制订重症肺结核共识,提出定义、三型分型诊断标准及19条推荐,覆盖抗结核治疗、呼吸循环支持、营养、康复等12方面。

中华医学会结核病学分会组织国内专家制订《重症肺结核诊断和治疗专家共识》,围绕重症肺结核的定义、分型、高危因素、抗结核治疗、药物相互作用、糖皮质激素、营养支持、大咯血、循环支持、肝肾支持、呼吸支持与院感防控、康复治疗共12方面形成19条推荐意见。共识将重症肺结核定义为出现严重肺组织损伤或功能不全伴严重低氧血症、伴或不伴严重并发症的肺结核,并分为严重肺组织损伤型、严重并发症型、危重症型三型,给出各型诊断标准。推荐意见按GRADE分级标注证据等级与推荐强度,为重症肺结核的规范化诊疗提供决策依据。

要点

  • 重症肺结核定义:严重肺组织损伤或功能不全伴严重低氧血症,伴或不伴严重并发症(2,C)。
  • 分三型:严重肺组织损伤型、严重并发症型、危重症型;Ⅰ、Ⅱ型均需PaO2/FiO2≤300 mmHg或PaO2≤60 mmHg(2,C)。
  • 危重症型为合并休克或多器官衰竭需入ICU行呼吸、循环或其他器官支持者(2,C)。
  • 高危因素包括糖尿病、高龄、营养不良、免疫抑制状态、肾功能不全、耐多药结核病(1,B)。
  • 合并HIV者应在启动抗结核治疗2周内尽快开始抗逆转录病毒治疗,疗程至少与HIV阴性患者相同(1,B)。

适用人群与场景

  • 肺结核患者进展为重症者,即出现严重肺组织损伤或功能不全伴严重低氧血症,伴或不伴严重并发症的肺结核患者。
  • 合并胃肠道功能障碍、HIV感染、ARDS、大咯血、循环功能障碍、脓毒性休克、严重肾功能衰竭、肝损伤、呼吸衰竭等并发症的重症肺结核患者。

诊断标准与关键阈值

  • 严重肺组织损伤型:需同时满足(1)结核病灶范围累及≤2个肺野伴干酪性实变、空洞坏死等,或病灶范围累及≥3个肺野,或气管狭窄;(2)氧合指数(PaO2/FiO2)≤300 mmHg或动脉血氧分压(PaO2)≤60 mmHg(1 mmHg=0.133 kPa)(2,C)。
  • 严重并发症型:肺结核伴以下任一严重并发症,同时PaO2/FiO2≤300 mmHg或PaO2≤60 mmHg:(1)中心气道狭窄;(2)大咯血;(3)张力性气胸;(4)呼吸频率≥30次/min;(5)心力衰竭;(6)肝功能衰竭;(7)肾功能衰竭;(8)意识障碍和/或定向障碍(2,C)。
  • 危重症型:肺结核伴休克或多器官衰竭,需入ICU行呼吸、循环或其他器官支持(2,C)。
  • 重症肺结核高危因素:糖尿病、高龄、营养不良、免疫抑制状态、肾功能不全、耐多药结核病(MDR-TB)(1,B)。

处置流程与药物剂量

  • 抗结核治疗遵循早期、联合、规律、适量、全程、个体化原则,在标准化一线方案基础上可依据患者具体病情选用高效、低毒二线抗结核药物(2,B)。
  • 临床情况允许时尽早启动抗结核治疗,依据患者器官功能选择合适药物(2,B)。
  • 合并胃肠道功能障碍者建议早期静脉滴注抗结核药物以快速达到并维持治疗血药浓度,病情稳定后逐步过渡至口服(2,C)。
  • 抗结核药物与多种抗真菌药物存在相互作用,建议依据患者病情和药物相互作用类型选择抗结核与抗真菌药物(1,B)。
  • 合并HIV感染者应尽快启动抗逆转录病毒治疗(ART),最好在启动抗结核治疗2周内开始,抗结核与抗逆转录病毒药物选择依据病情和药物相互作用(1,B)。
  • 合并ARDS者在抗结核治疗有效的前提下可给予糖皮质激素辅助治疗(1,B)。
  • 推荐对重症肺结核患者行营养风险筛查,对无肠内营养禁忌证且血流动力学稳定者早期进行肠内营养,可改善预后、降低病死率(1,B)。
  • 合并大咯血者必须快速解除呼吸道梗阻、保证氧供,病情稳定后行胸部CT血管造影(CTA),必要时考虑血管介入治疗或外科手术干预(1,C)。

红旗征与不能漏的情况

  • 合并大咯血:必须快速解除呼吸道梗阻、保证氧气吸入,待病情稳定后完善CTA检查,行血管介入或外科手术治疗(1,C)。
  • 合并循环功能障碍:应行无创/有创血流动力学监测,同时给予液体复苏和血管活性药物支持治疗(1,B)。
  • 合并脓毒性休克:建议早期启动细胞因子吸附治疗(2,C)。
  • 合并严重肾功能衰竭:应考虑肾脏替代治疗(2,B)。
  • 合并肝损伤:需密切监测,停用肝毒性高发药物,并给予保肝治疗和支持治疗等综合治疗(2,B)。
  • 合并呼吸衰竭:推荐实施个性化呼吸支持方式(1,B);合并ARDS者可考虑体外膜氧合(ECMO)治疗(2,C)。

研究设计与关键结果

  • 中华医学会结核病学分会组织国内专家制订本共识,在12个方面共形成19条推荐意见,为重症肺结核诊疗提供决策依据。
  • 共识推荐意见标注证据等级与推荐强度,包括(1,B)、(2,B)、(1,C)、(2,C)等级别。

证据类型、等级与局限

  • 证据类型:专家共识。
  • 推荐意见标注证据等级与推荐强度,如(1,B)、(2,B)、(1,C)、(2,C)。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 共识要求按三型诊断标准对重症肺结核分型,Ⅰ、Ⅱ型均以PaO2/FiO2≤300 mmHg或PaO2≤60 mmHg为低氧血症界值,危重症型以休克或多器官衰竭需入ICU器官支持界定(2,C)。
  • 对合并胃肠道功能障碍者,推荐早期静脉滴注抗结核药物以快速达到并维持治疗血药浓度,病情稳定后逐步过渡至口服(2,C)。
  • 对合并HIV感染者,推荐在启动抗结核治疗2周内尽快开始ART,疗程至少与HIV阴性患者相同(1,B)。
  • 对合并ARDS者,在抗结核治疗有效前提下可给予糖皮质激素辅助治疗(1,B);合并重度ARDS者可考虑ECMO治疗(2,C)。
  • 对无肠内营养禁忌证且血流动力学稳定者推荐早期肠内营养,可改善预后、降低病死率(1,B)。
  • 推荐对重症肺结核患者实施早期康复治疗,康复前进行安全性评估,实时监测生命体征变化,必要时及时中止(2,B)。
  • 需注意呼吸治疗相关高风险操作的感控管理(2,C)。

指南或共识出处

  • 《重症肺结核诊断和治疗专家共识》,中华医学会结核病学分会。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Patients with pulmonary tuberculosis (PTB) progressing severe conditions have a poor prognosis and high mortality. To enhance the scientificity and standardization of the diagnosis and treatment of severe PTB, the Chinese Society of Tuberculosis of Chinese Medical Association organized domestic experts to formulate the "Expert Consensus on the Diagnosis and Treatment of Severe Pulmonary Tuberculosis". The consensus presents 19 recommendation statements across the following 12 aspects, aiming to provide a decision-making basis for improving the management of severe PTB.The recommendations are listed below:Recommendation 1: Severe pulmonary tuberculosis refers to PTB accompanied with severe pulmonary parenchymal damage or functional impairment with severe hypoxemia, with or without serious complications (2, C).Recommendation 2: Based on clinical characteristics, severe PTB can be classified into the following three types, with diagnostic criteria as follows:Type Ⅰ: Severe Pulmonary Parenchymal Damage Type: Both of the following criteria must be met: (1) PTB lesion extent involving ≤2 lung fields accompanied by caseous consolidation, cavitary necrosis, etc., OR lesion extent involving ≥3 lung fields, OR tracheal stenosis; (2) Oxygenation index (PaO2/FiO2)≤300 mmHg or arterial partial pressure of oxygen (PaO2)≤60 mmHg (1 mmHg=0.133 kPa).Type Ⅱ: Severe Complication Type: PTB with any one of the following severe complications, concurrently with PaO2/FiO2≤300 mmHg or PaO2≤60 mmHg: (1) Central airway stenosis; (2) Massive hemoptysis; (3) Tension pneumothorax; (4) Respiratory rate ≥30 breaths/min; (5) Heart failure; (6) Liver failure; (7) Renal failure; (8) Impaired consciousness and/or disorientation.Type Ⅲ: Critical Illness Type: PTB with shock or multiple organ failure requiring admission to the ICU for respiratory, circulatory, or other organ support (2, C).Recommendation 3: Diabetes mellitus, advanced age, malnutrition, immunosuppressed status, renal insufficiency, and multidrug-resistant tuberculosis (MDR-TB) are high-risk factors for severe PTB (1, B).Recommendation 4: The anti-tuberculosis treatment for severe PTB follows the principles of early, combined, regular, adequate, full-course, and individualized therapy. Based on standardized first-line regimens, high-efficacy, low-toxicity second-line anti-TB drugs may be selected based on the patient's specific condition (2, B).Recommendation 5: For patients with severe PTB, it is recommended to initiate anti-TB treatment as early as possible when the clinical condition permits. Drug selection should be appropriate based on the patient's organ function (2, B).Recommendation 6: For severe PTB patients complicated with gastrointestinal dysfunction, it is recommended to initiate intravenous administration of anti-TB drugs early to rapidly achieve and maintain therapeutic blood drug levels, transitioning to oral administration gradually once the condition stabilizes (2, C).Recommendation 7: Interactions exist between anti-TB drugs and various antifungal agents. It is recommended to select anti-TB and antifungal drugs based on the patient's condition and the type of drug interactions (1, B).Recommendation 8: For severe PTB patients with HIV infection, antiretroviral therapy (ART) should be initiated as soon as possible, preferably within 2 weeks of initiating anti-TB treatment. The selection of anti-TB and antiretroviral drugs should be based on the patient's condition and drug interactions (1, B).Recommendation 9: For severe PTB patients with acute respiratory distress syndrome (ARDS), corticosteroid adjuvant therapy may be administered, under the premise of effective anti-tuberculosis treatment(1, B).Recommendation 10: Nutritional risk screening is recommended for patients with severe PTB. Early enteral nutrition for hemodynamically stable patients can improve prognosis and reduce mortality (1, B).Recommendation 11: For severe PTB patients with massive hemoptysis, rapid relief of airway obstruction and ensuring oxygen delivery are mandatory. After stabilization, computed tomography angiography (CTA) of the chest should be performed. Vascular interventional therapy or surgical intervention should be considered if necessary (1, C).Recommendation 12: For severe PTB patients with circulatory dysfunction, non-invasive/invasive hemodynamic monitoring should be performed, accompanied by fluid resuscitation and vasoactive drug support therapy (1, B).Recommendation 13: For patients with septic shock, early initiation of cytokine adsorption therapy is suggested (2, C).Recommendation 14: For severe PTB patients with severe renal failure, renal replacement therapy should be considered (2, B).Recommendation 15: For severe PTB patients with hepatic injury, close monitoring is essential. Drugs with a high incidence of hepatotoxicity should be discontinued, and comprehensive treatment including hepatoprotective therapy and supportive care should be provided (2, B).Recommendation 16: For severe PTB patients with respiratory failure, personalized respiratory support modalities is recommended (1, B).Recommendation 17: Attention must be paid to infection control management related to high-risk respiratory therapy operations for severe PTB patients (2, C).Recommendation 18: Extracorporeal membrane oxygenation (ECMO) therapy can be considered for severe PTB patients with ARDS (2, C).Recommendation 19: Early rehabilitation therapy is recommended for severe PTB patients. Safety assessment should be conducted prior to rehabilitation, with real-time monitoring of vital signs and rehabilitation should be terminated promptly if necessary(2, B).

肺结核患者进展为重症后预后差、病死率高,为提高重症肺结核诊疗的科学性和规范性,中华医学会结核病学分会组织国内相关专家制订了《重症肺结核诊断和治疗专家共识》。本共识在以下12方面共形成19条推荐意见,希望为提高重症肺结核诊疗的科学性和规范性提供决策依据。(1)重症肺结核定义:重症肺结核是指出现严重的肺组织损伤或功能不全伴严重低氧血症,伴或不伴严重并发症的肺结核。(2)重症肺结核分型:分为严重肺组织损伤型、严重并发症型、危重症型三型。(3)重症肺结核高危因素:糖尿病、高龄、营养不良、免疫抑制状态、肾功能不全、耐多药结核病。(4)重症肺结核的治疗:强调尽早启动抗结核治疗,在标准化方案基础上可依据患者的具体病情选用高效、低毒二线药物,需关注合并脓毒性休克者药代动力学和药效学的变化,建议对合并胃肠道功能障碍者早期给予静脉滴注抗结核药物治疗;(5)药物相互作用:多种抗结核药物是CYP3A4的诱导剂或抑制剂,可与多种抗真菌药物、抗逆转录病毒药物间存在相互作用导致药物活性和浓度的改变,可能诱发严重的不良反应,强调合理用药;合并HIV的重症肺结核患者在启动抗结核治疗2周内需尽快开始抗逆转录病毒治疗,疗程至少与HIV阴性患者相同,推荐固定复合剂量给药;(6)糖皮质激素的使用:对于合并急性呼吸窘迫综合征(ARDS)的重症肺结核患者,在抗结核治疗有效的前提下可给予糖皮质激素辅助治疗;(7)重症肺结核的营养支持治疗:需对重症肺结核患者行营养筛查,危重症患者早期采用允许性低热量营养策略,治疗中需遵循五阶梯治疗原则,推荐对无肠内营养禁忌证并且血流动力学稳定的重症肺结核患者早期进行肠内营养;(8)大咯血的处理:对于重症肺结核合并大咯血者,必须快速解除呼吸道梗阻,保证氧气吸入,待病情稳定后完善CT血管造影检查,行血管介入或外科手术治疗。(9)循环支持治疗:对重症肺结核合并循环功能障碍者可早期给予晶体液复苏及血管活性药物支持,对合并脓毒症休克者建议早期启动细胞因子吸附治疗;(10)肝脏、肾脏支持治疗:重症肺结核患者肝损伤风险高,根据肝损伤程度给予对症支持治疗;合并肾功能不全时可行肾脏替代治疗;(11)呼吸支持治疗及院感防控:重症肺结核导致呼吸衰竭时推荐实施个性化的呼吸支持方式,同时需注意呼吸治疗相关高风险操作的感控管理,对于合并重度ARDS的重症肺结核患者可采用体外膜氧合治疗;(12)康复治疗:对于重症肺结核患者建议实施早期康复治疗,康复前进行安全性评估,实时监测生命体征变化,必要时及时中止。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

参考来源

  1. [Expert consensus on the diagnosis and treatment of severe pulmonary tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 41362141. doi:10.3760/cma.j.cn112147-20250722-00429

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。